Page 2,505«..1020..2,5042,5052,5062,507..2,5102,520..»

Diane Winokur, Veteran ALS Patient Advocate, Named to California Stem Cell Agency Board

Posted: December 2, 2012 at 7:58 am


Longtime ALS patient advocate Diane
Winokur
of San Francisco, who has lost two sons to the disease, has
been appointed to the governing board of the $3 billion California
stem cell agency.

She fills the vacancy left by David
Serrano Sewell
, who resigned from the 29-member panel earlier this
year after serving since the agency's inception. CIRM has 10 patient advocates
on its board.
Diane Winokur
Photo -- Legal Momentum
Winokur is well-known in ALS circles.
She sat for five years on the governing board of the national ALS
advocacy group and currently serves on the board for the California
state group, the Golden West chapter. She also served for six years on the board of
trustees for the Sanford- Burnham Institute in La Jolla, which has received $37 million from the stem cell agency. She left Sanford in 2011.
Last summer Winokur appeared before the
CIRM board to successfully seek approval of an $18 million ALS grant
that was rejected by the agency's reviewers. Researcher Clive
Svendsen
of Cedars-Sinai in Los Angeles appealed the denial to the
full board and was supported in emotional testimony by other patient
advocates as well, including persons with the affliction.(See here for video of some of the testimony.)
The agency has awarded about $30.6
million, including the Svendsen grant, for research directly related
to ALS.
Golden
West issued a press release Nov. 21, lauding the Winokur appointment
by California Lt. Gov. Gavin Newsom. The release quoted Lucie Bruijn,
chief scientist of The ALS Association, as saying,

"Her
contributions have been invaluable and she will be a tremendous asset
in moving the ALS research field forward through CIRM
funding."

The stem cell agency posted a blog item
on Winokur's appointment in addition to a press release. CIRM
Chairman J.T. Thomas said,

“Her knowledge, expertise and
leadership will be a tremendous addition to the ICOC (the stem cell
agency governing board) and help guide us in our work.”

Patient advocate Don Reed of Fremont,
Ca., described Winokur in a 2008 blog item as “small, elegant, full
of energy, an exclamation point of a person.”

(Editor's note: Based on information from CIRM and Golden West, an earlier version of this item incorrectly stated that Winokur is a current member of the Sanford-Burnham board.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/dITcyP7WJbs/diane-winokur-veteran-als-patient.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Diane Winokur, Veteran ALS Patient Advocate, Named to California Stem Cell Agency Board

Knoepfler Award Update: More than a Baker's Dozen Nominated

Posted: December 2, 2012 at 7:58 am


As of this week, 14 persons have been
recommended for the Knoepfler “Stem Cell Person of the Year”
Award.

The total was reported by Paul
Knoepfler
, the UC Davis stem cell scientist and blogger, who is
putting up $1,000 for the winner of the honor.
Knoepfler announced his award plans earlier this month, declaring that he wanted to recognize scientists or others who “truly made a difference” in the stem
field. Risk-taking is one important criteria.
Knoepfler said,

“It’s something that I’m hoping I
can do every year. It would also be a reward for risk taking,
creativity and be breaking with tradition and be something new in
that regard.” 

The award has drawn some modest
attention outside of Knoepfler's blog. A few days after he introduced
the award on his blog, UC Davis decided to put out a press release and video on it. The California Stem Cell Report followed with an item. Then CIRM blogged it as well.
So far we have not detected any stories
about the award in the mainstream media, but things could change.
Deadline for entries is Dec. 17.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/cLYLc5HQUSY/knoepfler-award-update-more-than-bakers.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Knoepfler Award Update: More than a Baker's Dozen Nominated

.Rejuvenare Stem Cell Therapy 888-988-5456 – Video

Posted: December 2, 2012 at 6:44 am


.Rejuvenare Stem Cell Therapy 888-988-5456
Rejuvenare Autologous Adult Stem Cell Therapy welcome video asks and answers questions on whether someone is a candidate for stem cell therapy. More can be found at http://www.rejuvenare.comFrom:rejuvenareViews:0 0ratingsTime:01:01More inPeople Blogs

See the rest here:
.Rejuvenare Stem Cell Therapy 888-988-5456 - Video

Posted in Cell Therapy | Comments Off on .Rejuvenare Stem Cell Therapy 888-988-5456 – Video

QualityStocks News – International Stem Cell Corp. Advances Groundbreaking Stem Cell Therapy with Distinct Advantages …

Posted: December 2, 2012 at 6:44 am

Company's ability to do something nobody has done before confirms world-leader status.

Scottsdale, AZ (PRWEB) November 30, 2012

In the companys news yesterday,

International Stem Cell Corp. has achieved a critical milestone towards the clinical development of its non-embryonic stem cell therapy.

Through much dedication and hard work, the companys research and development team has created the worlds first human clinical-grade stem cell lines that can be immune-match to millions of individuals. ISCOs existing research-grade parthenogenetic stem cell lines, one of which may be an immune-match to approximately 70 million people, are being used in pre-clinical development. ISCO is now in a position to conduct clinical trials in the United States.

Weve been working diligently for three years to perfect this technology, which was first developed by our scientific founder, Dr. Elena Revazova in Moscow, and Im excited to report that we have been able to derive new stem cell lines in the United States under the US and California regulatory frameworks. Im optimistic that the new parthenogenetic stem cell lines, by providing a potentially unlimited supply of cells and tissue for transplantation, will be of great benefit to the medical community and patients world-wide, stated Dr. Semechkin, CEO and Co-Chairman of the Board.

Created using ISCOs proprietary technology, the new stem cell lines represent the first of a new generation of clinical-grade human parthenogenetic stem cell (hpSC) lines created in the United States under US regulatory oversight and designed to meet FDA regulations. The US Food and Drug Administration developed Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards to ensure the safety of products developed for clinical use. Conforming to GMP is necessary to conduct clinical development programs.

Independent third-party testing has confirmed the new lines to be homozygous in the HLA coding regions. This means that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection; a distinct clinical advantage over embryonic stem cells. The company anticipates the new lines to immune-match millions of individuals. They will be added to ISCOs existing bank and provide a platform from which to develop cells and tissue for clinical use.

The importance of this breakthrough cannot be overstated, emphasized Dr. Craw, Executive Vice President of ISCO. Expanding our collection is not only important for our therapeutic programs, but also further establishes our leadership position in human stem cell technology. Achieving this critical milestone moves us along the path to make the transition into a clinical stage company.

About QualityStocks

More here:
QualityStocks News - International Stem Cell Corp. Advances Groundbreaking Stem Cell Therapy with Distinct Advantages ...

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on QualityStocks News – International Stem Cell Corp. Advances Groundbreaking Stem Cell Therapy with Distinct Advantages …

Autologous Cell Therapy Market expected to reach $2.2 billion by 2017, growing at a CAGR of 21% : MarketsandMarkets

Posted: December 2, 2012 at 1:42 am

Autologous Cell Therapy Market reserach report gives a detailed analysis about state of the art of both autologous stem cell and non-stem cell treatments. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally.

(PRWEB) November 30, 2012

Browse ACT market research data tables/figures spread through 111 slides and in-depth TOC on Autologous Cell Therapy (ACT) Market (2012 - 2017).

http://www.marketsandmarkets.com/Market-Reports/autologous-cell-therapy-market-837.html

Early buyers will receive 10% customization on reports.

There is a wide market potential and favorable landscape for adoption across many geographical locations of the world. During the forecast period, these technologies are expected to revolutionize the area of bio-pharma and personalized medicine. High incidence and lack of effective treatment for several diseases will drive the ACT technology in developed and developing nations.

Investment activities, for past five years are actively held in research and developments, attracting interests of cell therapy industry firms, medical centers and academic institutions. ACT potential can be demonstrated by mergers, collaborations, acquisitions and partnerships that happened actively between the ACT technology developing companies in past three years. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market.

The global market for ACT is valued around $650 million by 2011 with a CAGR of 21%. Several products and technologies of ACT are in pipeline which is expected to hit the market during the forecast period, which will result in increased growth rate.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.

Read the rest here:
Autologous Cell Therapy Market expected to reach $2.2 billion by 2017, growing at a CAGR of 21% : MarketsandMarkets

Posted in Cell Therapy | Comments Off on Autologous Cell Therapy Market expected to reach $2.2 billion by 2017, growing at a CAGR of 21% : MarketsandMarkets

Stem Cells the Nephilim Chuck Missler 4 6 – Video

Posted: November 30, 2012 at 3:42 pm


Stem Cells the Nephilim Chuck Missler 4 6
From:Jesus IsraelViews:10 0ratingsTime:10:01More inNews Politics

Visit link:
Stem Cells the Nephilim Chuck Missler 4 6 - Video

Posted in Stem Cell Videos | Comments Off on Stem Cells the Nephilim Chuck Missler 4 6 – Video

Stem Cells the Nephilim Chuck Missler 3 6 – Video

Posted: November 30, 2012 at 3:42 pm


Stem Cells the Nephilim Chuck Missler 3 6
From:Jesus IsraelViews:17 0ratingsTime:10:01More inEducation

Go here to see the original:
Stem Cells the Nephilim Chuck Missler 3 6 - Video

Posted in Stem Cell Videos | Comments Off on Stem Cells the Nephilim Chuck Missler 3 6 – Video

Stem Cells the Nephilim Chuck Missler 2 6 – Video

Posted: November 30, 2012 at 3:42 pm


Stem Cells the Nephilim Chuck Missler 2 6
From:Jesus IsraelViews:1 0ratingsTime:10:01More inNews Politics

Read more here:
Stem Cells the Nephilim Chuck Missler 2 6 - Video

Posted in Stem Cell Videos | Comments Off on Stem Cells the Nephilim Chuck Missler 2 6 – Video

Stem Cells the Nephilim Chuck Missler 1 6 – Video

Posted: November 30, 2012 at 3:42 pm


Stem Cells the Nephilim Chuck Missler 1 6
From:Jesus IsraelViews:0 0ratingsTime:10:01More inEducation

Read more:
Stem Cells the Nephilim Chuck Missler 1 6 - Video

Posted in Stem Cell Videos | Comments Off on Stem Cells the Nephilim Chuck Missler 1 6 – Video

World’s 1st Human Embryonic Stem Cell Trial for Spinal Cord Injury – Katie Sharify’s Story – Video

Posted: November 30, 2012 at 3:42 pm


World #39;s 1st Human Embryonic Stem Cell Trial for Spinal Cord Injury - Katie Sharify #39;s Story
Katie Sharify was one of five people with spinal cord injuries to participate in the world #39;s first clinical trial testing human embryonic stem cells. The Geron sponsored trial was supported by California #39;s Stem Cell Agency (CIRM). In this video Katie speaks about her clinical trial experience with a group of scientists who were meeting to discuss the best ways of advancing stem cell clinical trials. CIRM communications manager Amy Adams interviewed Katie and her doctor, Stephen McKenna. To learn more about the efforts of California #39;s Stem Cell Agency (CIRM) to accelerate the development of new therapies for chronic disease and injury, visit our home page at: http://www.cirm.ca.gov For more information about CIRM-funded spinal cord injury research, visit our fact sheet http://www.cirm.ca.govFrom:CIRMTVViews:173 6ratingsTime:28:45More inScience Technology

Original post:
World's 1st Human Embryonic Stem Cell Trial for Spinal Cord Injury - Katie Sharify's Story - Video

Posted in Stem Cell Videos | Comments Off on World’s 1st Human Embryonic Stem Cell Trial for Spinal Cord Injury – Katie Sharify’s Story – Video

Page 2,505«..1020..2,5042,5052,5062,507..2,5102,520..»